Novartis Culls Fevipiprant After LackLUSTER Data
Asthma Pill Fails Second Set Of Studies
Executive Summary
Any lingering hopes Novartis had that fevipiprant could become a blockbuster have disappeared and the Swiss major has ended development of the asthma drug after two more trials failed, this time for severe disease.